EMPEROR-Reduced
Empagliflozin Outcome Trial in Chronic Heart Failure With Reduced EF
Patient / Population Intervention / Exposure Comparison Outcome
In 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
N
3,730
Design
Double-blind RCT
Endpoint
CV death or HF hospitalisation
Relevance
2
Result19.4 % vs 24.7 % (HR 0.75); slower decline in renal function.
Packer M, et al. N Engl J Med. 2020;383(15):1413-1424. 10.1056/NEJMoa2022190
Discussion & critique
Confirmed the SGLT2-inhibitor class effect alongside DAPA-HF. No clear mortality signal individually; the pooled HFrEF data show consistent benefit.